Dietary Conjugated Linoleic Acid Protects Against end Stage Disease of Systemic Lupus Erythematosus in the NZB/W F1 Mouse
Abstract Conjugated linoleic acid (CLA) is a naturally occurring fatty acid with anti-carcinogenic, anti-atherosclerotic and immune-enhancing activities. Dietary CLA accelerated the onset of proteinuria in autoimmune-prone NZB/W F1 mice but did not affect anti-DNA antibody production. Body weight of...
Gespeichert in:
| Veröffentlicht in: | Immunopharmacology and immunotoxicology 2000-01, Vol.22 (3), p.433-449 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 449 |
|---|---|
| container_issue | 3 |
| container_start_page | 433 |
| container_title | Immunopharmacology and immunotoxicology |
| container_volume | 22 |
| creator | Yang, Mingder Pariza, Michael W. Cook, Mark E. |
| description | Abstract
Conjugated linoleic acid (CLA) is a naturally occurring fatty acid with anti-carcinogenic, anti-atherosclerotic and immune-enhancing activities. Dietary CLA accelerated the onset of proteinuria in autoimmune-prone NZB/W F1 mice but did not affect anti-DNA antibody production. Body weight of the CLA group was decreased compared to the control group at the time proteinuria first developed. CLA group also had slightly earlier mortality than control fed mice, however the mean days of survival did not differ between CLA and control fed mice. Body weight loss between proteinuria onset and death was approximately twice as much in the control group as in the CLA group. Moreover, duration between proteinuria and death was longer in the CLA than in the control group. Our data suggested that dietary CLA may accelerate the autoimmune symptoms of NZB/W F1 mice, however, CLA protected against the disease related body weight loss and prolonged survival after proteinuria. |
| doi_str_mv | 10.3109/08923970009026004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17676708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17676708</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-ebcb511ca0f16d0cc612f622f4fc6e32b99d6cdb941cf325d663ce45ea151f363</originalsourceid><addsrcrecordid>eNp9kF1LHDEUhoNUdP34Ab0puerdaD5m4g7tzbpqK6ytoCL0ZsgkJ7tZZpJtkqHMv2-W9aJSlFyEw3nel8OD0EdKzjgl9TmZ1ozXF4SQmjBBSLmHJrTirGAV5R_QZLsvMsAP0VGMa0JohqsDdJjDpZiycoLGKwtJhhHPvVsPS5lA44V1vgOr8ExZje-DT6BSxLOltC4mDE7jhySXgK9sBBkBe4Mfxpigz5nFsBkivg5jWkEvk495sg7nCf_4dXn-jG8ovvNDhBO0b2QX4fTlP0ZPN9eP8-_F4ue32_lsUaiS81RAq9qKUiWJoUITpQRlRjBmSqMEcNbWtRZKt3VJleGs0kJwBWUFklbUcMGP0edd7yb43wPE1PQ2Kug66SDf0dALkR-ZZpDuQBV8jAFMswm2z24aSpqt7-Y_3znz6aV8aHvQ_yR2gjPwdQdYZ3zo5R8fOt0kOXY-mCCdsnHb_Xb_l1fxFcgurZQM0Kz9EFwW9851fwGGtKCn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17676708</pqid></control><display><type>article</type><title>Dietary Conjugated Linoleic Acid Protects Against end Stage Disease of Systemic Lupus Erythematosus in the NZB/W F1 Mouse</title><source>Taylor & Francis</source><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Yang, Mingder ; Pariza, Michael W. ; Cook, Mark E.</creator><creatorcontrib>Yang, Mingder ; Pariza, Michael W. ; Cook, Mark E.</creatorcontrib><description>Abstract
Conjugated linoleic acid (CLA) is a naturally occurring fatty acid with anti-carcinogenic, anti-atherosclerotic and immune-enhancing activities. Dietary CLA accelerated the onset of proteinuria in autoimmune-prone NZB/W F1 mice but did not affect anti-DNA antibody production. Body weight of the CLA group was decreased compared to the control group at the time proteinuria first developed. CLA group also had slightly earlier mortality than control fed mice, however the mean days of survival did not differ between CLA and control fed mice. Body weight loss between proteinuria onset and death was approximately twice as much in the control group as in the CLA group. Moreover, duration between proteinuria and death was longer in the CLA than in the control group. Our data suggested that dietary CLA may accelerate the autoimmune symptoms of NZB/W F1 mice, however, CLA protected against the disease related body weight loss and prolonged survival after proteinuria.</description><identifier>ISSN: 0892-3973</identifier><identifier>EISSN: 1532-2513</identifier><identifier>DOI: 10.3109/08923970009026004</identifier><identifier>PMID: 10946824</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Animals ; anti-DNA antibodies ; Antibodies, Antinuclear - biosynthesis ; Dietary Fats, Unsaturated - pharmacology ; Female ; linoleic acid ; Linoleic Acid - pharmacology ; Lupus Erythematosus, Systemic - diet therapy ; Lupus Erythematosus, Systemic - etiology ; Lupus Erythematosus, Systemic - pathology ; Mice ; Mice, Inbred NZB ; Proteinuria - etiology ; Weight Loss - drug effects</subject><ispartof>Immunopharmacology and immunotoxicology, 2000-01, Vol.22 (3), p.433-449</ispartof><rights>2000 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-ebcb511ca0f16d0cc612f622f4fc6e32b99d6cdb941cf325d663ce45ea151f363</citedby><cites>FETCH-LOGICAL-c433t-ebcb511ca0f16d0cc612f622f4fc6e32b99d6cdb941cf325d663ce45ea151f363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/08923970009026004$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/08923970009026004$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10946824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Mingder</creatorcontrib><creatorcontrib>Pariza, Michael W.</creatorcontrib><creatorcontrib>Cook, Mark E.</creatorcontrib><title>Dietary Conjugated Linoleic Acid Protects Against end Stage Disease of Systemic Lupus Erythematosus in the NZB/W F1 Mouse</title><title>Immunopharmacology and immunotoxicology</title><addtitle>Immunopharmacol Immunotoxicol</addtitle><description>Abstract
Conjugated linoleic acid (CLA) is a naturally occurring fatty acid with anti-carcinogenic, anti-atherosclerotic and immune-enhancing activities. Dietary CLA accelerated the onset of proteinuria in autoimmune-prone NZB/W F1 mice but did not affect anti-DNA antibody production. Body weight of the CLA group was decreased compared to the control group at the time proteinuria first developed. CLA group also had slightly earlier mortality than control fed mice, however the mean days of survival did not differ between CLA and control fed mice. Body weight loss between proteinuria onset and death was approximately twice as much in the control group as in the CLA group. Moreover, duration between proteinuria and death was longer in the CLA than in the control group. Our data suggested that dietary CLA may accelerate the autoimmune symptoms of NZB/W F1 mice, however, CLA protected against the disease related body weight loss and prolonged survival after proteinuria.</description><subject>Animals</subject><subject>anti-DNA antibodies</subject><subject>Antibodies, Antinuclear - biosynthesis</subject><subject>Dietary Fats, Unsaturated - pharmacology</subject><subject>Female</subject><subject>linoleic acid</subject><subject>Linoleic Acid - pharmacology</subject><subject>Lupus Erythematosus, Systemic - diet therapy</subject><subject>Lupus Erythematosus, Systemic - etiology</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Mice</subject><subject>Mice, Inbred NZB</subject><subject>Proteinuria - etiology</subject><subject>Weight Loss - drug effects</subject><issn>0892-3973</issn><issn>1532-2513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1LHDEUhoNUdP34Ab0puerdaD5m4g7tzbpqK6ytoCL0ZsgkJ7tZZpJtkqHMv2-W9aJSlFyEw3nel8OD0EdKzjgl9TmZ1ozXF4SQmjBBSLmHJrTirGAV5R_QZLsvMsAP0VGMa0JohqsDdJjDpZiycoLGKwtJhhHPvVsPS5lA44V1vgOr8ExZje-DT6BSxLOltC4mDE7jhySXgK9sBBkBe4Mfxpigz5nFsBkivg5jWkEvk495sg7nCf_4dXn-jG8ovvNDhBO0b2QX4fTlP0ZPN9eP8-_F4ue32_lsUaiS81RAq9qKUiWJoUITpQRlRjBmSqMEcNbWtRZKt3VJleGs0kJwBWUFklbUcMGP0edd7yb43wPE1PQ2Kug66SDf0dALkR-ZZpDuQBV8jAFMswm2z24aSpqt7-Y_3znz6aV8aHvQ_yR2gjPwdQdYZ3zo5R8fOt0kOXY-mCCdsnHb_Xb_l1fxFcgurZQM0Kz9EFwW9851fwGGtKCn</recordid><startdate>20000101</startdate><enddate>20000101</enddate><creator>Yang, Mingder</creator><creator>Pariza, Michael W.</creator><creator>Cook, Mark E.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20000101</creationdate><title>Dietary Conjugated Linoleic Acid Protects Against end Stage Disease of Systemic Lupus Erythematosus in the NZB/W F1 Mouse</title><author>Yang, Mingder ; Pariza, Michael W. ; Cook, Mark E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-ebcb511ca0f16d0cc612f622f4fc6e32b99d6cdb941cf325d663ce45ea151f363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>anti-DNA antibodies</topic><topic>Antibodies, Antinuclear - biosynthesis</topic><topic>Dietary Fats, Unsaturated - pharmacology</topic><topic>Female</topic><topic>linoleic acid</topic><topic>Linoleic Acid - pharmacology</topic><topic>Lupus Erythematosus, Systemic - diet therapy</topic><topic>Lupus Erythematosus, Systemic - etiology</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Mice</topic><topic>Mice, Inbred NZB</topic><topic>Proteinuria - etiology</topic><topic>Weight Loss - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Mingder</creatorcontrib><creatorcontrib>Pariza, Michael W.</creatorcontrib><creatorcontrib>Cook, Mark E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Immunopharmacology and immunotoxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Mingder</au><au>Pariza, Michael W.</au><au>Cook, Mark E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dietary Conjugated Linoleic Acid Protects Against end Stage Disease of Systemic Lupus Erythematosus in the NZB/W F1 Mouse</atitle><jtitle>Immunopharmacology and immunotoxicology</jtitle><addtitle>Immunopharmacol Immunotoxicol</addtitle><date>2000-01-01</date><risdate>2000</risdate><volume>22</volume><issue>3</issue><spage>433</spage><epage>449</epage><pages>433-449</pages><issn>0892-3973</issn><eissn>1532-2513</eissn><abstract>Abstract
Conjugated linoleic acid (CLA) is a naturally occurring fatty acid with anti-carcinogenic, anti-atherosclerotic and immune-enhancing activities. Dietary CLA accelerated the onset of proteinuria in autoimmune-prone NZB/W F1 mice but did not affect anti-DNA antibody production. Body weight of the CLA group was decreased compared to the control group at the time proteinuria first developed. CLA group also had slightly earlier mortality than control fed mice, however the mean days of survival did not differ between CLA and control fed mice. Body weight loss between proteinuria onset and death was approximately twice as much in the control group as in the CLA group. Moreover, duration between proteinuria and death was longer in the CLA than in the control group. Our data suggested that dietary CLA may accelerate the autoimmune symptoms of NZB/W F1 mice, however, CLA protected against the disease related body weight loss and prolonged survival after proteinuria.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>10946824</pmid><doi>10.3109/08923970009026004</doi><tpages>17</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0892-3973 |
| ispartof | Immunopharmacology and immunotoxicology, 2000-01, Vol.22 (3), p.433-449 |
| issn | 0892-3973 1532-2513 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17676708 |
| source | Taylor & Francis; MEDLINE; Taylor & Francis Medical Library - CRKN |
| subjects | Animals anti-DNA antibodies Antibodies, Antinuclear - biosynthesis Dietary Fats, Unsaturated - pharmacology Female linoleic acid Linoleic Acid - pharmacology Lupus Erythematosus, Systemic - diet therapy Lupus Erythematosus, Systemic - etiology Lupus Erythematosus, Systemic - pathology Mice Mice, Inbred NZB Proteinuria - etiology Weight Loss - drug effects |
| title | Dietary Conjugated Linoleic Acid Protects Against end Stage Disease of Systemic Lupus Erythematosus in the NZB/W F1 Mouse |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T11%3A37%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dietary%20Conjugated%20Linoleic%20Acid%20Protects%20Against%20end%20Stage%20Disease%20of%20Systemic%20Lupus%20Erythematosus%20in%20the%20NZB/W%20F1%20Mouse&rft.jtitle=Immunopharmacology%20and%20immunotoxicology&rft.au=Yang,%20Mingder&rft.date=2000-01-01&rft.volume=22&rft.issue=3&rft.spage=433&rft.epage=449&rft.pages=433-449&rft.issn=0892-3973&rft.eissn=1532-2513&rft_id=info:doi/10.3109/08923970009026004&rft_dat=%3Cproquest_cross%3E17676708%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17676708&rft_id=info:pmid/10946824&rfr_iscdi=true |